TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9257360

Group type: EXPERIMENTAL
Intervention: Hygroscopic condenser humidifier (HCH) during quiet breathing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hygroscopic condenser humidifier (HCH) during maximal voluntary ventilation (MVV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Without HCH during quiet breathing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Without HCH during maximal voluntary ventilation (MVV)
Number of subjects: 21
Study: 8227822

Group type: EXPERIMENTAL
Intervention: Quinapril (n = 114)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (n = 110)
Number of subjects: 224
Study: 3081399

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo, arbacet, misoprostol, sucralfate, and pirenzepine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs
Number of subjects: 86
Study: 29705448

Group type: EXPERIMENTAL
Intervention: Natural sounds for 30 minutes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Classical Turkish Music for 30 minutes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Western Music for 30 minutes
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 180
Study: 27729323

Group type: EXPERIMENTAL
Intervention: Serum free light chain (sFLC) measurements
Number of subjects: 113

Group type: COMPARATOR
Intervention: Urine protein electrophoresis (UPEP)
Number of subjects: 113
Study: 24646858

Group type: EXPERIMENTAL
Intervention: Mean baseline 24‐h urinary sodium excretion of 3.46 g/day
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Urine sodium under 3 g/day
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Urine sodium ⩾ 3 g/day
Number of subjects: 840
Study: 22531306

Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cold knife tonsillectomy
Number of subjects: 91
Study: 20447935

Group type: EXPERIMENTAL
Intervention: Intervention colleges (15) with Campus Advisory Boards and facilitated activities
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control colleges (15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intervention colleges (15)
Number of subjects: 30
Study: 18988091

Group type: EXPERIMENTAL
Intervention: SPF50 sunscreen lotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPF50 sunscreen spray lotion
Number of subjects: 0
Study: 16195164

Group type: EXPERIMENTAL
Intervention: 5 g of the herbal remedy made from Rosa canina daily for 3 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 12866240

Group type: EXPERIMENTAL
Intervention: Training module for ultrasound-guided breast biopsy skills
Number of subjects: 12

Group type: COMPARATOR
Intervention: No training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Training for USGBB in inexperienced residents (n = 4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Training for USGBB in US-experienced residents (n = 2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untrained US-experienced residents (n = 3)
Number of subjects: 12
Study: 10934079

Group type: EXPERIMENTAL
Intervention: Preovulatory phase (Days 5 to 11)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Periovulatory phase (Days 12 to 18)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Postovulatory phase (Days 19 to 25)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Perimenstrual phase (Days 26 to 4)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Overall classification of ED visits by menstrual phase
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Asthma severity
Number of subjects: 288
Study: 9505981

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350/electrolyte solution
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 57
Study: 8445442

Group type: EXPERIMENTAL
Intervention: Ethamsylate (12.5 mg/kg) given prophylactically within the first 4 hours of life followed by 6-hourly doses for 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study: 3705790

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support pessary
Number of subjects: 0
Study: 31409166

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (400 mg cyclogest vaginal suppositories once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular progesterone (250 mg of 17-hydroxyprogesterone caproate weekly)
Number of subjects: 100
Study: 31558379

Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition supplementation
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 180
Study: 31204416

Group type: EXPERIMENTAL
Intervention: Phytosomal Curcumin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 29046364

Group type: EXPERIMENTAL
Intervention: IV prochlorperazine + diphenhydramine
Number of subjects: 127

Group type: COMPARATOR
Intervention: IV hydromorphone
Number of subjects: 127
Study: 25392319

Group type: EXPERIMENTAL
Intervention: Subcutaneous Interferon beta (IFNb)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of biomarkers (CASP2/IRF4/IRF6)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of biomarkers (CASP2/IL10/IL12Rb1)
Number of subjects: 180
Study: 23522849

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 271
Study: 20558036

Group type: EXPERIMENTAL
Intervention: New drug with no side effects, no additional visit required, balanced information provided, results in the public domain, project approved by a research ethics committee.
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Destruction of blood samples at the end of the project, use of placebo controls, random allocation to study arms.
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Origin of funds, financial reward, need to complete a questionnaire, clinical vs. economic purpose of the study.
Number of subjects: 1277
Study: 18578802

Group type: EXPERIMENTAL
Intervention: Community nursing services (home visits)
Number of subjects: 46
Study: 16544149

Group type: EXPERIMENTAL
Intervention: Endo-anal pudendal nerve stimulation daily at home with a portable home unit
Number of subjects: 48

Group type: COMPARATOR
Intervention: Endo-anal electrical stimulation under supervision in physiotherapy department
Number of subjects: 48
Study: 12842509

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass (CABG)
Number of subjects: 1090
Study: 10666428

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1208
Study: 8558203

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (5 mg/kg bolus over 3 hours followed by 15 mg/kg infusion over 24 hours) plus paclitaxel (200 mg/m2 over 3 hours)
Number of subjects: 26
Study: 1775272

Group type: EXPERIMENTAL
Intervention: Auto-oxygenation (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional technique with bubble oxygenator (group B)
Number of subjects: 40
Study: 6353927

Group type: EXPERIMENTAL
Intervention: 2 mg relaxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg relaxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30770754

Group type: EXPERIMENTAL
Intervention: CGMP-AA2
Number of subjects: 48

Group type: COMPARATOR
Intervention: L-AA
Number of subjects: 48
Study: 26945913

Group type: EXPERIMENTAL
Intervention: Home tele-rehabilitation system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-trial rehabilitation (control group)
Number of subjects: 0
Study: 26738667

Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time (SBT)
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Door-to-balloon time (DBT)
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Clinical risk factors (anterior infarction, reference vessel diameter, lesion minimum lumen diameter, hyperlipidemia, current smoking)
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Microvascular perfusion measures (MBG 0/1 and STR <30%)
Number of subjects: 2056
Study: 26021535

Group type: EXPERIMENTAL
Intervention: Transperitoneal (TP) approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retroperitoneal (RP) approach
Number of subjects: 100
Study: 21331637

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (5% sodium fluoride, Duraphat(®), Colgate) applied monthly for 6 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Saline solution (control) applied monthly for 6 months
Number of subjects: 110
Study: 19458299

Group type: EXPERIMENTAL
Intervention: Straight-tip Tenckhoff catheter with an artificial subcutaneous swan neck (TC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional double-cuff straight-tip swan-neck catheter (SN)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (TC and SN)
Number of subjects: 39
Study: 17635844

Group type: EXPERIMENTAL
Intervention: 1.87 mg triptorelin depot i.m. followed by daily s.c. injections of saline
Number of subjects: 182

Group type: COMPARATOR
Intervention: Reduced-dose daily buserelin (0.5 mg initially, reduced to 0.25 mg)
Number of subjects: 182
Study: 15682929

Group type: EXPERIMENTAL
Intervention: Gincosan (320mg/day, containing 120mg Ginkgo biloba and 200mg Panax ginseng)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 30
Study: 11579354

Group type: EXPERIMENTAL
Intervention: 0.625 mg of oral conjugated estrogens (Premarin) per day for 4 to 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9848785

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irbesartan (100 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d) + Indomethacin (75 mg twice a day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irbesartan (100 mg/d) + Indomethacin (75 mg twice a day)
Number of subjects: 20
Study: 7814791

Group type: EXPERIMENTAL
Intervention: Formal exercise conditioning program (3 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Formal exercise conditioning program (3 months and 12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care control group (n = 23, mean age 68 ± 5 years)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Formal exercise conditioning program
Number of subjects: 60
Study: 2354691

Group type: EXPERIMENTAL
Intervention: Toasted Am proteins (20%, 30%, and 50% replacement of M proteins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maize (M) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Am alone
Number of subjects: 0
Study: 6161868

Group type: EXPERIMENTAL
Intervention: Farial nose drops
Number of subjects: 64

Group type: COMPARATOR
Intervention: Xylometazoline-containing nose drops
Number of subjects: 64
Study: 28967201

Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: 5 mg solifenacin with placebo once daily for 8 weeks
Number of subjects: 92
Study: 26750772

Group type: EXPERIMENTAL
Intervention: CO-OP training
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: COMPUTER training
Number of subjects: 11
Study: 25382452

Group type: EXPERIMENTAL
Intervention: Carvedilol (titrated from 3.125 mg twice daily to 6.25 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 24938848

Group type: EXPERIMENTAL
Intervention: 7 days of additional noninvasive cardiac event monitoring with an R‐test device
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Any investigative modality for PAF detection
Number of subjects: 49
Study: 23237631

Group type: EXPERIMENTAL
Intervention: Acenocoumarol dosing algorithm based on demographic, clinical, and pharmacogenetic variables (VKORC1, CYP2C9, CYP4F2, ApoE)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (control group) with scheduled and adjusted acenocoumarol dose following common clinical practice
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acenocoumarol dosing algorithm
Number of subjects: 240
Study: 21290841

Group type: EXPERIMENTAL
Intervention: Acupuncture-assisted anesthesia (periprostatic nerve plexus block and acupuncture on bilateral Zusanli ST 36) in group A
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (simple periprostatic nerve plexus block) in group B
Number of subjects: 105
Study: 17876425

Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam (5 mg for those under 65 years, 2.5 mg for those aged 65 years or more)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 40
Study: 16230678

Group type: EXPERIMENTAL
Intervention: PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly cisplatin 40 mg/m2
Number of subjects: 0
Study: 11988242

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 250 microg administered every other day
Number of subjects: 188

Group type: COMPARATOR
Intervention: Interferon beta‐1a 30 microg administered once a week
Number of subjects: 188
Study: 10560984

Group type: EXPERIMENTAL
Intervention: Healthy young men
Number of subjects: 25
Study: 7569506

Group type: EXPERIMENTAL
Intervention: Dose-response information to support drug registration (especially dose/toxicity relationships)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies in support of special populations; Geriatrics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICH Draft Guideline 3 on the extent of population exposure required to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions
Number of subjects: 0
Study: 1978233

Group type: EXPERIMENTAL
Intervention: bopindolol (1‐3 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: metoprolol (100‐300 mg daily in two divided doses)
Number of subjects: 40
Study: 336412

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LH-RH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: All treatments (LH-RH, hCG, and placebo)
Number of subjects: 8
Study: 30578650

Group type: COMPARATOR
Intervention: Free-handed surgery (FH)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pilot-drill guided surgery (PG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fully guided surgery (FG)
Number of subjects: 33
Study: 29119732

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Group R, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warfarin (Group W, n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Group R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warfarin (Group W)
Number of subjects: 60
Study: 25259552

Group type: EXPERIMENTAL
Intervention: Cold water immersion (11°C)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tepid water immersion (26°C)
Number of subjects: 26
Study: 22985692

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg (three-times/day)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Inhaled tobramycin nebulizer solution (TNS) 300 mg (twice/day)
Number of subjects: 273
Study: 21219582

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 27
Study: 19101221

Group type: EXPERIMENTAL
Intervention: VASP-guided group (n = 215)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group (n = 214)
Number of subjects: 429
Study: 16764551

Group type: COMPARATOR
Intervention: Placebo techniques developed to mimic spinal manipulative therapy
Number of subjects: 25
Study: 15232758

Group type: EXPERIMENTAL
Intervention: Vaginal application of prostaglandin E2 (PGE2)
Number of subjects: 262
Study: 11713618

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg and 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9522696

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (conditioned dentin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single Bond (conditioned dentin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Syntac Sprint (conditioned dentin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (unconditioned dentin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single Bond (unconditioned dentin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Syntac Sprint (unconditioned dentin)
Number of subjects: 24
Study: 8698034

Group type: EXPERIMENTAL
Intervention: High interpersonal stress condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low interpersonal stress condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study: 2711967

Group type: EXPERIMENTAL
Intervention: 20 minutes of exercise at 25 W above lactate threshold (ALT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 minutes of exercise at 25 W below lactate threshold (BLT)
Number of subjects: 10
Study: 1089913

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.028 to 0.111 mg/kg)
Number of subjects: 10
Study: 31795875

Group type: EXPERIMENTAL
Intervention: 2-mA stimulation bilaterally over M1 (anode on the right M1 and cathode on the left M1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 31166680

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)
Number of subjects: 563
Study: 28760794

Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger and single vitrified-warmed blastocyst transfer in a subsequent hCG triggered natural menstrual cycle
Number of subjects: 424

Group type: COMPARATOR
Intervention: hCG trigger and single blastocyst transfer in the fresh (stimulated) cycle
Number of subjects: 424
Study: 25771895

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23749405

Group type: EXPERIMENTAL
Intervention: IDeg U100 (0.4 U/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IDeg U200 (0.4 U/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: IDeg U200
Number of subjects: 33

Group type: COMPARATOR
Intervention: IDeg U100
Number of subjects: 33
Study: 21525194

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides 2.5 g
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides 5.0 g
Number of subjects: 427

Group type: COMPARATOR
Intervention: Galactooligosaccharides 0 g (Control)
Number of subjects: 427
Study: 19561369

Group type: EXPERIMENTAL
Intervention: Pilates intervention (15 sessions of Pilates)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No Pilates intervention (control group)
Number of subjects: 28
Study: 16788276

Group type: EXPERIMENTAL
Intervention: Notified group (n=157)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Non-notified group (n=172)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Genotype ALDH2*1/*1
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Genotype ALDH2*1/*2
Number of subjects: 329
Study: 15446780

Group type: EXPERIMENTAL
Intervention: Educational intervention directed to change prescribing
Number of subjects: 61

Group type: COMPARATOR
Intervention: Practice groups participating in information exchange (n = 14)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Practice groups with a formulary (22 groups)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Practice groups using feedback data (22 groups)
Number of subjects: 61
Study: 11530125

Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg followed by misoprostol 400 microg orally (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg followed by misoprostol 800 microg vaginally (group 2)
Number of subjects: 80
Study: 9404564

Group type: EXPERIMENTAL
Intervention: High complement activation group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low complement activation group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sera obtained half a year before the season
Number of subjects: 22
Study: 12959295

Group type: EXPERIMENTAL
Intervention: Nifedipine with grapefruit juice (200 ml double strength)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nifedipine with quercetin (400 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 8
Study: 3126890

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (n = 32)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (n = 30)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Group therapy (n = 30)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Waiting list control (n = 20)
Number of subjects: 92
Study: 30119073

Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 28350652

Group type: EXPERIMENTAL
Intervention: Mitomycin C (topical application during surgery)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control (no mitomycin C)
Number of subjects: 322
Study: 25015650

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RAT) - 3 conventional therapy sessions and 2 robot-assisted sessions per week over 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional therapy - 5 sessions per week over 8 weeks
Number of subjects: 16
Study: 23618380

Group type: EXPERIMENTAL
Intervention: High tertile immune metagene expression in highly proliferative tumors
Number of subjects: 1954

Group type: EXPERIMENTAL
Intervention: Low tertile expression of any one of the three immune metagenes in highly proliferative tumors
Number of subjects: 1954
Study: 21205399

Group type: EXPERIMENTAL
Intervention: Oportunidades food supplement (OFS)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Powdered milk (PM)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 224